The round was led by Longitude Capital with participation from new investors Skandia and Silver Point Capital. Other current investors that participated in the financing include MPM Capital, AIG Investments's sponsored funds, Perseus-Soros Biopharmaceutical Fund, Blue Chip Venture Company, HealthCare Ventures, and Union Springs.

Aquilo Partners, a life science investment bank, acted as the exclusive placement agent for the financing.

Michael Valentino, president and CEO of Xanodyne, said: "I am extremely pleased to have secured additional financial resources which will be used to support our ongoing development and commercialization strategy for our emerging product portfolio."

A service of YellowBrix, Inc.